684 related articles for article (PubMed ID: 16943400)
21. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
Sandler RS; Halabi S; Baron JA; Budinger S; Paskett E; Keresztes R; Petrelli N; Pipas JM; Karp DD; Loprinzi CL; Steinbach G; Schilsky R
N Engl J Med; 2003 Mar; 348(10):883-90. PubMed ID: 12621132
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Bresalier RS; Sandler RS; Quan H; Bolognese JA; Oxenius B; Horgan K; Lines C; Riddell R; Morton D; Lanas A; Konstam MA; Baron JA;
N Engl J Med; 2005 Mar; 352(11):1092-102. PubMed ID: 15713943
[TBL] [Abstract][Full Text] [Related]
23. The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma.
Chan AT; Hsu M; Zauber AG; Hawk ET; Bertagnolli MM
Cancer Prev Res (Phila); 2012 Jan; 5(1):61-72. PubMed ID: 22030088
[TBL] [Abstract][Full Text] [Related]
24. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
Rahme E; Barkun AN; Toubouti Y; Bardou M
Gastroenterology; 2003 Aug; 125(2):404-12. PubMed ID: 12891542
[TBL] [Abstract][Full Text] [Related]
25. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Goldstein JL; Cryer B; Amer F; Hunt B
Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
[TBL] [Abstract][Full Text] [Related]
26. Risks and benefits of celecoxib to prevent colorectal adenomas.
Andersohn F; Suissa S; Garbe E
N Engl J Med; 2006 Nov; 355(22):2371; author reply 2371-3. PubMed ID: 17135594
[No Abstract] [Full Text] [Related]
27. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
Huang WF; Hsiao FY; Wen YW; Tsai YW
Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
[TBL] [Abstract][Full Text] [Related]
28. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL
Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563
[TBL] [Abstract][Full Text] [Related]
29. Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review.
Asano TK; McLeod RS
Dis Colon Rectum; 2004 May; 47(5):665-73. PubMed ID: 15054679
[TBL] [Abstract][Full Text] [Related]
30. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.
Chan AT; Zauber AG; Hsu M; Breazna A; Hunter DJ; Rosenstein RB; Eagle CJ; Hawk ET; Bertagnolli MM
Gastroenterology; 2009 Jun; 136(7):2127-2136.e1. PubMed ID: 19233181
[TBL] [Abstract][Full Text] [Related]
31. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
Chan FK; Hung LC; Suen BY; Wu JC; Lee KC; Leung VK; Hui AJ; To KF; Leung WK; Wong VW; Chung SC; Sung JJ
N Engl J Med; 2002 Dec; 347(26):2104-10. PubMed ID: 12501222
[TBL] [Abstract][Full Text] [Related]
32. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention.
Feng GS; Ma JL; Wong BC; Zhang L; Liu WD; Pan KF; Shen L; Zhang XD; Li J; Xia HH; Li JY; Lam SK; You WC
World J Gastroenterol; 2008 Jul; 14(28):4535-9. PubMed ID: 18680235
[TBL] [Abstract][Full Text] [Related]
33. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.
Chan FK; Wong VW; Suen BY; Wu JC; Ching JY; Hung LC; Hui AJ; Leung VK; Lee VW; Lai LH; Wong GL; Chow DK; To KF; Leung WK; Chiu PW; Lee YT; Lau JY; Chan HL; Ng EK; Sung JJ
Lancet; 2007 May; 369(9573):1621-6. PubMed ID: 17499604
[TBL] [Abstract][Full Text] [Related]
34. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
[TBL] [Abstract][Full Text] [Related]
35. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
Elmets CA; Viner JL; Pentland AP; Cantrell W; Lin HY; Bailey H; Kang S; Linden KG; Heffernan M; Duvic M; Richmond E; Elewski BE; Umar A; Bell W; Gordon GB
J Natl Cancer Inst; 2010 Dec; 102(24):1835-44. PubMed ID: 21115882
[TBL] [Abstract][Full Text] [Related]
36. Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention.
Thompson P; Roe DJ; Fales L; Buckmeier J; Wang F; Hamilton SR; Bhattacharyya A; Green S; Hsu CH; Chow HH; Ahnen DJ; Boland CR; Heigh RI; Fay DE; Martinez ME; Jacobs E; Ashbeck EL; Alberts DS; Lance P
Cancer Prev Res (Phila); 2012 Dec; 5(12):1381-93. PubMed ID: 23060037
[TBL] [Abstract][Full Text] [Related]
37. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.
Goldstein JL; Lowry SC; Lanza FL; Schwartz HI; Dodge WE
Aliment Pharmacol Ther; 2006 May; 23(10):1489-98. PubMed ID: 16669964
[TBL] [Abstract][Full Text] [Related]
38. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
Cole BF; Baron JA; Sandler RS; Haile RW; Ahnen DJ; Bresalier RS; McKeown-Eyssen G; Summers RW; Rothstein RI; Burke CA; Snover DC; Church TR; Allen JI; Robertson DJ; Beck GJ; Bond JH; Byers T; Mandel JS; Mott LA; Pearson LH; Barry EL; Rees JR; Marcon N; Saibil F; Ueland PM; Greenberg ER;
JAMA; 2007 Jun; 297(21):2351-9. PubMed ID: 17551129
[TBL] [Abstract][Full Text] [Related]
39. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
[TBL] [Abstract][Full Text] [Related]
40. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
